Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Gliquidone is a sulfonylurea drug used in the management of diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker.
- Mechanism
- Curator reviewed
The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.
- Primary indication
- Used in the treatment of diabetes mellitus type 2.Curator reviewed · 1 structured indication
- Formula / weight
- C27H33N3O6S · 527.632 g/mol (avg)
- Code names
- ARDF-26
Resolves to
LLJFMFZYVVLQKT-UHFFFAOYSA-NSMILESCOC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Gliquidone, and which of those have an active Phase 3 trial?